What is Titan Pharmaceut's earnings per share (EPS)?

Titan Pharmaceut (TTNP) reported diluted earnings per share of -$5.23 for fiscal year 2024. This represents a 29.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Titan Pharmaceut Financials

TTNP

FY2024 annual

Revenue Not reported for FY2024

Net Income -$4.7M +15.5% YoY

EPS (Diluted) -$5.23 +29.4% YoY

Free Cash Flow Not reported for FY2024

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2025, ended Jun 30, 2025 Reported Aug 14, 2025 Currency USD FYE December

This page shows Titan Pharmaceut (TTNP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TTNP FY2024 2026-08-30

External funding and development spending remain the dominant mechanics as commercial revenue stays too small to support operations.

Operating cash consumption exceeded the net loss in FY2023, with operating cash flow of -$7.09M against a net loss of -$5.57M, indicating that reported earnings understated cash needs that year. In FY2024, operating cash flow of -$3.88M remained negative while financing cash flow was only -$62K, a sharp contrast with the $10.0M financing inflow in FY2023; funding, rather than operating receipts, had been the more important cash source.

The FY2023 revenue base of $184K was dwarfed by R&D spending of $1.91M, showing a development-stage cost structure rather than a commercially scaled operation. Selling, general and administrative expense of $5.55M further explains why the operating loss reached -$7.28M despite limited reported sales.

The balance sheet became smaller but less encumbered: total liabilities fell from $1.44M in FY2023 to $483K in FY2024, while the current ratio increased from 5.6x to 6.1x. That liquidity profile coexists with continued operating cash use; the reported liquidity comparison was 8.8 months of the latest annual operating outflow, not internally generated cash.

Financial Health Signals

Financial health score not available

Titan Pharmaceut does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Titan Pharmaceut passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Titan Pharmaceut reported a net loss of $4.7M while operations used $3.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$4.6M

YoY+36.5%

Titan Pharmaceut's EBITDA was -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.5% from the prior year.

Net Income

-$4.7M

YoY+15.5%

Titan Pharmaceut reported -$4.7M in net income in fiscal year 2024. This represents an increase of 15.5% from the prior year.

EPS (Diluted)

-$5.23

YoY+29.4%

Titan Pharmaceut earned -$5.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 29.4% from the prior year.

Revenue

Not reported for fiscal year 2024.

Cash & Balance Sheet

Cash & Debt

$2.8M

YoY-58.1%

5Y CAGR-11.5%

10Y CAGR-15.6%

Titan Pharmaceut held $2.8M in cash as of fiscal year 2024; long-term debt is not reported for that period.

Shares Outstanding

914,234

YoY0.0%

Titan Pharmaceut had 914,234 shares outstanding in fiscal year 2024. That is unchanged from the prior year.

Free Cash Flow

Not reported for fiscal year 2024.

Dividends Per Share

Not reported for fiscal year 2024.

Margins & Returns

Return on Equity

-192.9%

YoY-109.0pp

5Y CAGR+955.6pp

10Y CAGR-165.0pp

Titan Pharmaceut's ROE was -192.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 109.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2024.

Operating Margin

Not reported for fiscal year 2024.

Net Margin

Not reported for fiscal year 2024.

Capital Allocation

None of these metrics is reported for fiscal year 2024.

TTNP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TTNP quarterly income statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Revenue	N/A	N/A	$184K-67.0%	$557K-63.5%	$1.5M-68.5%	$4.8M+85.7%	$2.6M-60.6%	$6.6M+2978.1%	$215K-98.6%	$15.1M+801.6%	$1.7M-54.2%	$3.6M-65.2%	$10.5M+47.3%	$7.1M+75.0%	$4.1M-59.7%	$10.1M
Cost of Revenue	N/A	N/A	N/A	N/A	$199K-57.8%	$472K	$0-100.0%	$538K	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$1.3M-69.6%	$4.4M+67.6%	$2.6M-57.2%	$6.1M+2727.9%	$215K-98.6%	$15.1M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$1.9M-59.8%	$4.8M-16.4%	$5.7M-3.8%	$5.9M+16.5%	$5.1M-32.1%	$7.5M-22.5%	$9.6M+57.5%	$6.1M+31.0%	$4.7M+14.7%	$4.1M-51.0%	$8.3M-21.7%	$10.6M-5.3%	$11.2M-12.8%	$12.9M
SG&A Expenses	N/A	$4.6M-17.9%	$5.5M-8.1%	$6.0M+20.9%	$5.0M-14.0%	$5.8M-51.4%	$11.9M+73.7%	$6.9M+35.5%	$5.1M+10.3%	$4.6M+22.4%	$3.8M+23.3%	$3.0M-0.6%	$3.1M-37.2%	$4.9M+44.8%	$3.4M+3.2%	$3.3M
Operating Income	N/A	-$4.6M+37.4%	-$7.3M+28.9%	-$10.2M-9.4%	-$9.4M-27.2%	-$7.4M+6.7%	-$7.9M+4.7%	-$8.3M+43.0%	-$14.5M-433.9%	$4.3M+164.3%	-$6.8M-94.5%	-$3.5M-290.0%	-$891K+89.4%	-$8.4M+20.3%	-$10.5M-74.4%	-$6.0M
Income Tax	N/A	$1K0.0%	$1K+125.0%	-$4K	$0	$0	$0	$0	$0	$0	$0+100.0%	-$1K-200.0%	$1K0.0%	$1K-80.0%	$5K	N/A
Net Income	N/A	-$4.7M+15.5%	-$5.6M+45.4%	-$10.2M-16.3%	-$8.8M+51.9%	-$18.2M-10.8%	-$16.5M-82.4%	-$9.0M+36.9%	-$14.3M-378.6%	$5.1M+145.5%	-$11.3M-369.4%	-$2.4M-124.7%	$9.7M+164.0%	-$15.2M+0.2%	-$15.2M-122.5%	-$6.8M
EPS (Diluted)	-$2.95	-$5.23+29.4%	-$7.41+51.2%	-$15.19	-$0.90+54.1%	-$1.96	-$0.72	-$1.66	-$4.22-451.7%	$1.20	-$0.56	-$0.20	$0.53	-$0.23+17.9%	-$0.28	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$424K
SG&A Expenses	$657K+23.0%	$534K	N/A	$754K-63.6%	$2.1M+95.1%	$1.1M	N/A	$1.6M
Operating Income	-$657K-23.0%	-$534K	N/A	-$754K+63.6%	-$2.1M-95.1%	-$1.1M	N/A	-$2.1M
Net Income	-$689K-22.4%	-$563K	N/A	-$763K+63.5%	-$2.1M-97.5%	-$1.1M	N/A	-$338K
EPS (Diluted)	-$0.65-4.8%	-$0.62+27.1%	-$0.85-2.4%	-$0.83+63.8%	-$2.29-84.7%	-$1.24+82.6%	-$7.14	-$0.45

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

TTNP Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TTNP quarterly balance sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Total Assets	$2.9M-63.9%	$8.1M+99.3%	$4.1M-49.2%	$8.0M-1.1%	$8.1M-15.1%	$9.5M-32.4%	$14.1M+58.3%	$8.9M-52.3%	$18.7M+40.5%	$13.3M-36.3%	$20.9M+13.2%	$18.4M-25.8%	$24.8M+143.0%	$10.2M+115.0%	$4.8M
Current Assets	$2.9M-63.5%	$8.0M+122.5%	$3.6M-50.2%	$7.2M-1.4%	$7.3M-11.8%	$8.3M-37.5%	$13.3M+60.1%	$8.3M-53.4%	$17.8M+45.6%	$12.2M-37.5%	$19.6M+16.4%	$16.8M-28.2%	$23.4M+135.2%	$10.0M+112.0%	$4.7M
Cash & Equivalents	$2.8M-58.1%	$6.8M+130.2%	$2.9M-51.4%	$6.0M+11.5%	$5.4M+3.6%	$5.2M-43.8%	$9.3M+23.6%	$7.5M-46.3%	$14.0M+78.3%	$7.9M-49.2%	$15.5M+31.1%	$11.8M-34.8%	$18.1M+234.9%	$5.4M+70.0%	$3.2M
Inventory	N/A	$0-100.0%	$106K-63.8%	$293K-10.7%	$328K-41.7%	$563K-55.4%	$1.3M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$46K+27.8%	$36K-67.9%	$112K-87.3%	$884K+101.8%	$438K-74.8%	$1.7M+2572.3%	$65K-98.2%	$3.6M-14.9%	$4.2M+6.2%	$4.0M-17.6%	$4.8M+3.7%	$4.6M+24.9%	$3.7M+203.7%	$1.2M
Total Liabilities	$483K-66.6%	$1.4M-46.4%	$2.7M-5.6%	$2.9M-37.3%	$4.6M-43.7%	$8.1M+11.4%	$7.3M-9.7%	$8.0M+47.0%	$5.5M-13.0%	$6.3M-48.6%	$12.2M-3.3%	$12.7M-73.6%	$48.0M+58.3%	$30.3M+180.4%	$10.8M
Current Liabilities	$483K-66.6%	$1.4M-45.1%	$2.6M-1.5%	$2.7M-36.8%	$4.2M+17.3%	$3.6M+4.3%	$3.5M-22.7%	$4.5M-8.1%	$4.9M+0.1%	$4.9M-27.2%	$6.7M-38.6%	$10.8M-49.3%	$21.4M+317.6%	$5.1M-5.2%	$5.4M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$332K-91.7%	$4.0M+6.1%	$3.8M+5.7%	$3.6M	$0	N/A	N/A	$0-100.0%	$9.4M-23.6%	$12.3M+126.9%	$5.4M
Total Equity	$2.4M-63.3%	$6.6M+387.3%	$1.4M-73.5%	$5.1M+45.5%	$3.5M+146.5%	$1.4M-79.0%	$6.8M+697.1%	$857K-93.5%	$13.2M+88.7%	$7.0M-18.8%	$8.6M+49.5%	$5.8M+124.9%	-$23.1M-15.2%	-$20.1M-231.7%	-$6.1M
Retained Earnings	-$396.5M-1.2%	-$391.8M-1.4%	-$386.3M-2.7%	-$376.1M-2.4%	-$367.3M-5.2%	-$349.0M-4.9%	-$332.6M-2.9%	-$323.3M-4.6%	-$309.0M+1.6%	-$314.1M-3.7%	-$302.8M-0.8%	-$300.4M+3.1%	-$310.1M-5.1%	-$294.9M-5.4%	-$279.7M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-17.2%	$4.3M-34.5%	$6.6M-17.8%	$8.1M-19.1%	$10.0M
Current Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-17.2%	$4.3M-34.2%	$6.6M-17.5%	$8.0M-19.0%	$9.9M
Cash & Equivalents	$2.8M+44.1%	$1.9M-31.3%	$2.8M-16.7%	$3.4M-16.9%	$4.1M-33.6%	$6.2M-8.9%	$6.8M-16.5%	$8.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Accounts Receivable	N/A	N/A	N/A	$38K0.0%	$38K-71.6%	$134K+191.3%	$46K+76.9%	$26K
Total Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K+4.2%	$356K-36.3%	$559K-61.3%	$1.4M-22.6%	$1.9M
Current Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K+4.2%	$356K-36.3%	$559K-61.3%	$1.4M-22.6%	$1.9M
Total Equity	$2.8M+48.5%	$1.9M-23.1%	$2.4M-24.5%	$3.2M-19.1%	$4.0M-34.4%	$6.1M-8.4%	$6.6M-18.3%	$8.1M
Retained Earnings	-$397.8M-0.2%	-$397.1M-0.1%	-$396.5M-0.2%	-$395.7M-0.2%	-$395.0M-0.5%	-$392.9M-0.3%	-$391.8M-0.4%	-$390.3M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

TTNP Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TTNP quarterly cash flow statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Operating Cash Flow	-$2.7M	-$3.9M+45.3%	-$7.1M+13.3%	-$8.2M-3.6%	-$7.9M+54.1%	-$17.2M-11.4%	-$15.4M-83.2%	-$8.4M+33.5%	-$12.7M-301.4%	$6.3M+184.3%	-$7.5M-27.3%	-$5.9M+40.1%	-$9.8M-635.5%	$1.8M+112.6%	-$14.5M-210.8%	-$4.7M
Capital Expenditures	N/A	N/A	$2K	N/A	$23K-95.7%	$540K+110.9%	$256K-38.5%	$416K+137.7%	$175K+2.3%	$171K+28.6%	$133K+638.9%	$18K-94.3%	$318K-72.4%	$1.2M+389.0%	$236K+742.9%	$28K
Free Cash Flow	N/A	N/A	-$7.1M	N/A	-$7.9M+55.4%	-$17.7M-13.0%	-$15.7M-77.5%	-$8.8M+31.2%	-$12.9M-309.9%	$6.1M+180.6%	-$7.6M-29.2%	-$5.9M+41.9%	-$10.1M-1596.6%	$676K+104.6%	-$14.7M-214.0%	-$4.7M
Investing Cash Flow	N/A	N/A	$732K	N/A	-$23K+95.7%	-$540K-110.9%	-$256K+38.5%	-$416K-137.7%	-$175K-2.3%	-$171K-28.6%	-$133K	N/A	N/A	-$1.2M-393.2%	-$234K-735.7%	-$28K
Financing Cash Flow	N/A	-$62K-100.6%	$10.0M+100.6%	$5.0M-43.6%	$8.8M-50.7%	$17.9M+59.1%	$11.3M+6.1%	$10.6M+57.8%	$6.7M+24822.2%	$27K+292.9%	-$14K	N/A	N/A	$12.0M-29.0%	$16.9M+271.0%	$4.6M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$680K+21.6%	-$867K-71.3%	-$506K+27.0%	-$693K+66.5%	-$2.1M-237.4%	-$613K	N/A	-$1.8M
Financing Cash Flow	$1.5M+8194.7%	-$19K	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

TTNP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

TTNP quarterly financial ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Gross Margin	N/A	N/A	N/A	87.0%-3.3pp	90.2%-9.8pp	100.0%+8.1pp	91.9%-8.1pp	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-3954.9%	-1837.5%	-613.0%	-151.9%	-302.3%	-124.9%	-6745.1%	28.8%	-404.5%	-95.3%-86.8pp	-8.5%	-117.6%	-258.3%	-59.7%
Net Margin	N/A	-3026.6%	-1832.3%	-575.1%	-377.1%	-631.8%	-136.3%	-6654.4%	34.1%	-675.0%	-65.9%-158.6pp	92.7%	-213.3%	-373.7%	-67.7%
Return on Equity	-192.9%-109.0pp	-83.9%+664.9pp	-748.8%-578.0pp	-170.8%+345.7pp	-516.5%+632.0pp	-1148.5%-1016.4pp	-132.1%+1537.3pp	-1669.4%-1708.4pp	38.9%+200.3pp	-161.4%-133.4pp	-27.9%-196.5pp	168.6%	N/A	N/A	N/A
Return on Assets	-161.0%-92.1pp	-68.9%+182.6pp	-251.5%-141.7pp	-109.8%+115.8pp	-225.6%-52.7pp	-172.8%-108.8pp	-64.0%+96.6pp	-160.7%-188.2pp	27.5%+112.4pp	-84.9%-73.4pp	-11.5%-64.2pp	52.7%+113.9pp	-61.1%+87.7pp	-148.8%-5.0pp	-143.8%
Current Ratio	6.05+0.5x	5.55+4.2x	1.37-1.3x	2.71+1.0x	1.74-0.6x	2.31-1.5x	3.85+2.0x	1.86-1.8x	3.67+1.1x	2.52-0.4x	2.94+1.4x	1.55+0.5x	1.10-0.8x	1.94+1.1x	0.87
Debt-to-Equity	0.200.0x	0.22-1.8x	1.98+2.0x	0.00-0.1x	0.09-2.7x	2.80+2.3x	0.55-3.6x	4.18+4.2x	0.00-0.9x	0.90-0.5x	1.42+1.4x	0.00	N/A	N/A	N/A
FCF Margin	N/A	-3855.4%	N/A	-519.1%	-366.7%	-602.7%	-133.7%	-5977.7%	40.6%	-454.8%	-161.3%	-96.5%-106.0pp	9.5%	-361.6%	-46.4%

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-51525.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-8450.0%
Return on Equity	-24.7%+5.3pp	-30.0%	N/A	-23.6%+28.8pp	-52.4%-35.0pp	-17.4%	N/A	-4.2%
Return on Assets	-22.6%+3.5pp	-26.1%	N/A	-21.2%+26.9pp	-48.1%-32.2pp	-16.0%	N/A	-3.4%
Current Ratio	11.60+3.9x	7.73+1.7x	6.05-3.7x	9.71-2.5x	12.22+0.4x	11.83+6.3x	5.55+0.2x	5.30
Debt-to-Equity	0.09-0.1x	0.150.0x	0.20+0.1x	0.110.0x	0.090.0x	0.09-0.1x	0.220.0x	0.23

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

60 degrees pharmaceuticals, Inc. SXTP

$3.6M

Polyrizon Ltd PLRZ

$27.4M

Ensysce Biosciences Inc ENSC

$7.8M

Pasithea Therapeutics Corp KTTA

$18.7M

Palisade Bio Inc PALI

$348.5M

Where Titan Pharmaceut Ranks

Frequently Asked Questions

Is Titan Pharmaceut profitable?

No, Titan Pharmaceut (TTNP) reported a net income of -$4.7M in fiscal year 2024.

What is Titan Pharmaceut's EBITDA?

Titan Pharmaceut (TTNP) had EBITDA of -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Titan Pharmaceut's return on equity (ROE)?

Titan Pharmaceut (TTNP) has a return on equity of -192.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Titan Pharmaceut's operating cash flow?

Titan Pharmaceut (TTNP) recorded an outflow of $3.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are Titan Pharmaceut's total assets?

Titan Pharmaceut (TTNP) had $2.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Titan Pharmaceut have outstanding?

Titan Pharmaceut (TTNP) had 914,234 shares outstanding as of fiscal year 2024.

What is Titan Pharmaceut's current ratio?

Titan Pharmaceut (TTNP) had a current ratio of 6.05 as of fiscal year 2024, which is generally considered healthy.

What is Titan Pharmaceut's debt-to-equity ratio?

Titan Pharmaceut (TTNP) had a debt-to-equity ratio of 0.20 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Titan Pharmaceut's return on assets (ROA)?

Titan Pharmaceut (TTNP) had a return on assets of -161.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

How does Titan Pharmaceut's liquidity compare with its operating cash outflow?

At the end of fiscal year 2024, Titan Pharmaceut (TTNP) held $2.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.9M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Titan Pharmaceut's Piotroski F-Score?

Titan Pharmaceut (TTNP) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Titan Pharmaceut's earnings high quality?

Titan Pharmaceut (TTNP) reported a net loss of $4.7M while operations used $3.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.